# BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer

> **NCT02155088** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 15 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** BYL719
- **DRUG:** Gemcitabine
- **DRUG:** (nab)-paclitaxel

## Key facts

- **NCT ID:** NCT02155088
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-30
- **Primary completion:** 2016-12-01
- **Final completion:** 2020-01-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02155088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02155088, "BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02155088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*